Valfix

Valfix

lamivudine

Manufacturer:

Y.S.P. Industries

Distributor:

Y.S.P. Industries
Concise Prescribing Info
Contents
Lamivudine
Indications/Uses
100 mg: Chronic hepatitis B & evidence of HBV replication. 150 mg: In combination w/ other antiretroviral agents for HIV infected adults & childn.
Dosage/Direction for Use
100 mg Patient ≥16 yr 100 mg once daily. 150 mg Adult & adolescent at least 30 kg 150 mg bd or 300 mg once daily. CrCl 30 to <50 mL/min Initially 150 mg. Maintenance: 150 mg once daily, 15 to <30 mL/min Initially 150 mg. Maintenance: 100 mg once daily, 5 to <15 mL/min Initially 150 mg. Maintenance: 50 mg once daily, <5 mL/min Initially 50 mg. Maintenance: 25 mg once daily. Childn >3 mth, 21-30 kg 75 mg in the morning & 150 mg in the evening, 14-21 kg 75 mg bd. Childn >3 mth, <30 kg & CrCl 30 to <50 mL/min Initially 4 mg/kg. Maintenance: 4 mg/kg once daily, 15 to <30 mL/min Initially 4 mg/kg. Maintenance: 2.6 mg/kg once daily, 5 to <15 mL/min Initially 4 mg/kg. Maintenance: 1.3 mg/kg once daily, <5 mL/min Initially 1.3 mg/kg. Maintenance: 0.7 mg/kg once daily.
Administration
May be taken with or without food.
Contraindications
Special Precautions
Moderate to severe renal impairment. Pregnancy & lactation. 100 mg: Not recommended in decompensated hepatic disease. Exacerbation of hepatitis. Periodically monitor serum hepatic function tests (ALT & bilirubin levels) for at least 4 mth for evidence of recurrent hepatitis. Co-infected w/ HIV & currently or planning to receive antiretroviral regimen. Patients receiving immunosuppressive regimens including cancer chemotherapy. Transplantation & advance hepatic disease. 150 mg: Not to be used as monotherapy. Discontinue use if pancreatitis occur. Opportunistic infections; mitochondrial dysfunction following exposure in utero; osteonecrosis; immune reactivation syndrome. Patients w/ chronic hepatitis B or C. Monitor hepatic function tests & HBV replication markers; blood lipid & glucose level. Concomitant use as triple nucleoside therapy.
Adverse Reactions
Headache, nausea, vomiting, diarrhoea, fatigue, malaise. 100 mg: Resp tract infections; abdominal discomfort & pain. 150 mg: Hyperlactataemia, upper abdominal pain, rash, alopecia, arthralgia, muscle disorders, fever.
Drug Interactions
Concomitant use w/ other cytidine analogues eg, emtricitabine. 100 mg: Inhibited intracellular phosphorylation of zalcitabine. 150 mg: Increased exposure w/ trimethoprim/sulfamethoxazole. Increased Cmax of zidovudine. Inhibited intracellular phosphorylation of cladribine.
MIMS Class
Antivirals
ATC Classification
J05AF05 - lamivudine ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Presentation/Packing
Form
Valfix FC tab 100 mg
Packing/Price
10 × 10's;100 × 10's;3 × 10's;50 × 10's;6 × 10's
Form
Valfix FC tab 150 mg
Packing/Price
12 × 10's;3 × 10's;6 × 10's
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in